CDX 0158

Drug Profile

CDX 0158

Alternative Names: CDX-0159; KTN 0158

Latest Information Update: 01 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Toronto; Yale University School of Medicine
  • Developer Celldex Therapeutics Inc
  • Class Antiallergics; Antiasthmatics; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Receptor protein-tyrosine kinase antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Inflammation
  • Research Neurofibromatoses

Most Recent Events

  • 29 Nov 2016 Kolltan Pharmaceuticals has been acquired and merged into Celldex Therapeutics Inc
  • 20 Apr 2016 Preclinical data from a preclinical tria in Cancer presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 18 Jan 2016 Kolltan plans to file an IND application with the US FDA for Neurofibromatosis in 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top